Efficacy and safety study to assess between two drugs (Inhaler) in patients with Chronic Obstructive Pulmonary Disease

Phase 3

Recruiting

• Conditions: Chronic obstructive pulmonary disease, unspecified,

• Registration Number: CTRI/2023/01/048645
• Lead Sponsor: Lupin Limited

Brief Summary

A Multi-center, Randomized,Open-label, Comparative, Parallel Group study to assess the efficacy and safety of a fixed dose combination ofLupin’s Glycopyrronium + Vilanteroldry powder inhaler versus fixed dose combination of Glycopyrronium + Formoterol dry powder inhalerin patients with Chronicobstructive pulmonary disease.

 Approximately 14 weeks

 Screening up to 10 days{including run-in period of atleast 7 days}

 Treatment period: 12 weeks]

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-01
• Last Update Posted: 2023-09-02

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Male or female patients, aged ≥18 to ≤ 75 years at screening 2.
• Patients with a diagnosis of COPD (as defined by the GOLD Guidelines, 2021) 3.
• Post-bronchodilator FEV1 ≥30% and <80% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) ratio < 0.70 4.
• COPD treatment stable dose of maintenance monotherapy (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or ICS/LABA), for one month prior to screening 6.
• Current or previous cigarette/beedi smokers with a history of cigarette/beedi smoking of at least 10 pack/years.
• (Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Screening Visit.).

Exclusion Criteria

• Subjects who will not meet any of the following criteria will be included in the trial: 1.
• Patients who are currently receiving dual drug treatment with LABA+LAMA 2.
• Known respiratory disorders other than COPD including, but not limited to the following: tuberculosis, alpha-1 antitrypsin deficiency, cystic fibrosis, asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease 3.
• Evidence or history of other clinically significant cardiovascular disease or abnormality (such as, but not limited to, congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, arrhythmia, long QT syndrome, atrial fibrillation), renal, neurological, endocrine, immunological, psychiatric, hepatic, or hematological disease or abnormality which, in the opinion of the investigator, are clinically significant and would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study 4.
• No significant abnormality that suggests chest disease other than COPD, on chest X-ray or computed tomography (CT) scan taken within six months before screening.
• If there is no chest X-ray/CT scan is taken within six months prior to screening, a chest X-ray will be performed during screening to rule out any other significant abnormality.
• History of paradoxical bronchospasm, narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, or severe renal impairment or urinary retention or any other condition, which, in the opinion of the investigator, would contraindicate the use of an anticholinergic or long-acting beta-agonist agent 6.
• History of allergy or hypersensitivity to any of the ingredients of study drugs or components of the delivery system 7.
• Suspected or confirmed SARS-COV2 infection at screening (prior to randomization the subjects will be tested for COVID 19 through rapid antigen test).
• 8.Hospitalization for COPD exacerbation or pneumonia within three months prior to screening.
• Any subject who experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded.
• Clinically significant abnormal electrocardiogram (ECG) finding at screening.
• Lung volume reduction surgery within 12 months prior to the initiation of the study.
• Requirement of long term (> 12 hours daily) oxygen therapy 12.
• Unable to stop the following medications at the defined times prior to screening spirometry: Medication Required washout period prior to screening spirometry Ipratropium or ipratropium/salbutamol 8 Hrs combination product Inhaled short acting β-agonists 6 hours Oral β 2-agonists 48 hours Long acting β-agonists (salmeterol and formoterol) or ICS/LABA combination products 48 hours Xanthines 48 hours Cromolyn and nedocromil inhalers 24 hours Zafirlukast, montelukast, zileuton 48 hours Long-acting anticholinergics (Tiotropium etc.) 48 hours Oral or parenteral corticosteroids 6 weeks Any other investigational medication 30 days or 5 half-lives of the investigational drug (whichever is longer) Depot corticosteroids 3 months Inhaled corticosteroids (ICS) Washout not required 13.Currently enrolled in another interventional clinical study or have used any IPs, study drug, or device within 30 days or 5 times the half-life, whichever was longer preceding informed consent or scheduled to participate in another clinical study involving an IP.
• Additional exclusion criteria for Run-In period: COPD exacerbation requiring treatment with antibiotics, systemic corticosteroids (oral or intravenous), and/or a hospitalization during screening and run-in period.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
•Change from baseline in trough FEV1	week 12

Secondary Outcome Measures

Name	Time	Method
1.Change from baseline in trough FEV1	2. Change from baseline in 2 h post-dose FEV1

Trial Locations

Locations (12)

Apollo Specialty Hospital Pvt. Ltd.; 🇮🇳 Nagar, UTTAR PRADESH, India

Asian Institute of Medical Sciences (AIMS); 🇮🇳 Thane, MAHARASHTRA, India

Excel Hospital; 🇮🇳 Medchal, TELANGANA, India

G.S.V.M Medical College; 🇮🇳 Nagar, UTTAR PRADESH, India

Ishwar Institute of Health Care; 🇮🇳 Aurangabad, MAHARASHTRA, India

Jawahar Lal Nehru Medical College; 🇮🇳 Ajmer, RAJASTHAN, India

Lifepoint Multispecialty Hospital; 🇮🇳 Pune, MAHARASHTRA, India

Maharaja Agrasen Superspeciality Hospital; 🇮🇳 Jaipur, RAJASTHAN, India

Pt. B. D. Sharma, PGIMS; 🇮🇳 Rohtak, HARYANA, India

Samvedna Hospital; 🇮🇳 Varanasi, UTTAR PRADESH, India

Scroll for more (2 remaining)

Apollo Specialty Hospital Pvt. Ltd.

🇮🇳Nagar, UTTAR PRADESH, India

Dr Sandeep Katiyar

Principal investigator

9889888080

skkatiyarin@gmail.com